Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | LQDA | Common Stock | Award | $0 | +154K | +11.11% | $0.00 | 1.54M | Mar 31, 2022 | See footnote | F1, F2 |
holding | LQDA | Common Stock | 112K | Mar 31, 2022 | Direct | ||||||
holding | LQDA | Common Stock | 6.1K | Mar 31, 2022 | See footnote | F3 |
Id | Content |
---|---|
F1 | On March 31, 2022, 154,167 shares of the Issuer's common stock which were previously subject to a holdback pursuant to the terms of the merger agreement for Issuer's acquisition of RareGen, LLC ("RareGen") were released to the Reporting Person. The merger agreement provided that certain shares of the Issuer's common stock issuable to members of RareGen at the closing of the transaction would be held back as partial security for the benefit of the Issuer with respect to any indemnifiable damages pursuant to the indemnification obligations of the members of RareGen. The shares would subsequently be released for no additional consideration, subject to the cancellation of shares of the Issuer's common stock in connection with any such indemnifiable damages. |
F2 | The securities are held by Serendipity BioPharma LLC ("Serendipity"). The Reporting Person is a manager of Serendipity and has sole voting and dispositive power over the Issuer common stock held by Serendipity. |
F3 | The securities are held by Roger A. Jeffs 2019 GRAT dtd 05/01/2019 (the "Trust"). The Reporting Person is the trustee of the Trust. |